Y-mAbs Therapeutics

Antibody Therapies for Oncology

Also 2 additional trials Clin2 neuroblastoma, Clin2 osteosarcoma; GD2-GD3 Clin2 neuroblastoma; Omburtamab 4 trials Clin1/Clin2 multiple cancers; GD2-SADA Clin1 multiple cancers; CD38-SADA Clin0 NHL

Y-mAbs Therapeutics is focused on developing antibody-based immunotherapies for primarily pediatric, but also adult cancers. Their scientific focus centers on harnessing the specificity and targeting capabilities of antibodies to selectively bind to cancer cells and activate the immune system. Y-mAbs Therapeutics employs advanced biotechnology and antibody engineering techniques to enhance therapeutic efficacy and minimize side effects. Their pretargeted radioimmunotherapies, monoclonal and bispecific antibodies, and vaccines are specifically targeted and developed to address unmet medical needs for rare and challenging cancers. Y-mAbs is also developing companion diagnostics that measure biomarker tumor expression levels to improve the safety and effectiveness of their treatments.